Cargando…
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579050/ https://www.ncbi.nlm.nih.gov/pubmed/37814064 http://dx.doi.org/10.1038/s41591-023-02624-w |
| _version_ | 1785121635381018624 |
|---|---|
| author | Houot, Roch Bachy, Emmanuel Cartron, Guillaume Gros, François-Xavier Morschhauser, Franck Oberic, Lucie Gastinne, Thomas Feugier, Pierre Duléry, Rémy Thieblemont, Catherine Joris, Magalie Jardin, Fabrice Choquet, Sylvain Casasnovas, Olivier Brisou, Gabriel Cheminant, Morgane Bay, Jacques-Olivier Gutierrez, Francisco Llamas Menard, Cédric Tarte, Karin Delfau, Marie-Hélène Portugues, Cédric Itti, Emmanuel Palard-Novello, Xavier Blanc-Durand, Paul Al Tabaa, Yassine Bailly, Clément Laurent, Camille Lemonnier, François |
| author_facet | Houot, Roch Bachy, Emmanuel Cartron, Guillaume Gros, François-Xavier Morschhauser, Franck Oberic, Lucie Gastinne, Thomas Feugier, Pierre Duléry, Rémy Thieblemont, Catherine Joris, Magalie Jardin, Fabrice Choquet, Sylvain Casasnovas, Olivier Brisou, Gabriel Cheminant, Morgane Bay, Jacques-Olivier Gutierrez, Francisco Llamas Menard, Cédric Tarte, Karin Delfau, Marie-Hélène Portugues, Cédric Itti, Emmanuel Palard-Novello, Xavier Blanc-Durand, Paul Al Tabaa, Yassine Bailly, Clément Laurent, Camille Lemonnier, François |
| author_sort | Houot, Roch |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10579050 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105790502023-10-18 Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial Houot, Roch Bachy, Emmanuel Cartron, Guillaume Gros, François-Xavier Morschhauser, Franck Oberic, Lucie Gastinne, Thomas Feugier, Pierre Duléry, Rémy Thieblemont, Catherine Joris, Magalie Jardin, Fabrice Choquet, Sylvain Casasnovas, Olivier Brisou, Gabriel Cheminant, Morgane Bay, Jacques-Olivier Gutierrez, Francisco Llamas Menard, Cédric Tarte, Karin Delfau, Marie-Hélène Portugues, Cédric Itti, Emmanuel Palard-Novello, Xavier Blanc-Durand, Paul Al Tabaa, Yassine Bailly, Clément Laurent, Camille Lemonnier, François Nat Med Publisher Correction Nature Publishing Group US 2023-10-09 2023 /pmc/articles/PMC10579050/ /pubmed/37814064 http://dx.doi.org/10.1038/s41591-023-02624-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Publisher Correction Houot, Roch Bachy, Emmanuel Cartron, Guillaume Gros, François-Xavier Morschhauser, Franck Oberic, Lucie Gastinne, Thomas Feugier, Pierre Duléry, Rémy Thieblemont, Catherine Joris, Magalie Jardin, Fabrice Choquet, Sylvain Casasnovas, Olivier Brisou, Gabriel Cheminant, Morgane Bay, Jacques-Olivier Gutierrez, Francisco Llamas Menard, Cédric Tarte, Karin Delfau, Marie-Hélène Portugues, Cédric Itti, Emmanuel Palard-Novello, Xavier Blanc-Durand, Paul Al Tabaa, Yassine Bailly, Clément Laurent, Camille Lemonnier, François Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title | Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title_full | Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title_fullStr | Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title_full_unstemmed | Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title_short | Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| title_sort | publisher correction: axicabtagene ciloleucel as second-line therapy in large b cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial |
| topic | Publisher Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579050/ https://www.ncbi.nlm.nih.gov/pubmed/37814064 http://dx.doi.org/10.1038/s41591-023-02624-w |
| work_keys_str_mv | AT houotroch publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT bachyemmanuel publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT cartronguillaume publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT grosfrancoisxavier publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT morschhauserfranck publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT obericlucie publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT gastinnethomas publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT feugierpierre publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT duleryremy publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT thieblemontcatherine publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT jorismagalie publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT jardinfabrice publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT choquetsylvain publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT casasnovasolivier publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT brisougabriel publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT cheminantmorgane publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT bayjacquesolivier publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT gutierrezfranciscollamas publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT menardcedric publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT tartekarin publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT delfaumariehelene publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT portuguescedric publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT ittiemmanuel publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT palardnovelloxavier publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT blancdurandpaul publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT altabaayassine publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT baillyclement publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT laurentcamille publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial AT lemonnierfrancois publishercorrectionaxicabtageneciloleucelassecondlinetherapyinlargebcelllymphomaineligibleforautologousstemcelltransplantationaphase2trial |